Torrey Pines Institute for Molecular Studies science image
Torrey Pines Institute for
Molecular Studies
11350 SW Village Parkway
Port St. Lucie, FL 34987-2352
USA
Scientists
Jay McLaughlin
Associate Member
Pharmacology and Neuroscience

772.345.4715 - phone
772.345.3649 - fax
contact by email

Education

B A., Biology University of California at Santa Cruz
Santa Cruz, California - September 1985 - June 1989

M.S., Neuroscience University of Rochester School of Medicine and Dentistry - Rochester, New York
September 1992 - May 1996

Ph.D., Neuroscience University of Rochester School of Medicine and Dentistry - Rochester, New York
May 1996 - April 1998

Positions

Associate Member, Torrey Pines Institute for Molecular Studies, Port St. Lucie, Florida
January 2009 - Present

Assistant Professor, Northeastern University Boston, Massachusetts
August 2004 - 2009

Acting Assistant Professor, University of Washington - Seattle, Washington
October 2003 - August 2004

Acting Instructor, University of Washington - Seattle, Washington
February 2002 - October 2003

Postdoctoral Fellow, University of Washington - Seattle, Washington
September 1999 - February 2002

Postdoctoral Fellow, University of Rochester - Rochester, New York
April 1998 - July 1999

Production Technician: Genentech, Inc. - South San Francisco, California
January 1991 - June 1992

Research Technician: Cardiology laboratory of Robert Marshal
Veteran Affairs Hospital, Martinez - Martinez, California
August 1989 - July 1991

Publications

  1. Aldrich, JV, Patkar, KA, McLaughlin, JP. Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action. Proc Natl Acad Sci USA. 106(43):18396-401, 2009.
  2. Kulkarni, SS, Ross, NC, McLaughlin, JP, Aldrich, JV. Synthesis of cyclic tetrapeptide CJ 15,208: a novel kappa opioid receptor antagonist. Adv Exp Med Biol. 611:269-70, 2009.
  3. Aldrich, JV, McLaughlin, JP. Peptide kappa opioid receptor ligands: Potential for drug development. AAPS J. 11(2):312-22, 2009.
  4. McLaughlin, JP, Gomes, S, Seliga, A, Goyette, SR, Morrison, A, Reich, CG, Frye, CA. Northeast Under/graduate Research Organization for Neuroscience (NEURON): Our thirteenth conference for neuroscience trainees and educators. CBE-Life Sciences Education. 8(2):111-3, 2009.
  5. Carey, A.N., Lyons, A.M., Shay, C.F., Dunton, O., McLaughlin, J.P. Endogenous kappa opioid activation mediates stress-induced deficits in learning and memory. J. Neurosci. 29(13):4293-300, 2009.
  6. Reindl J.D., Rowan K, Carey A.N., Peng X., Neumeyer J.L. and McLaughlin, J.P.: Antidepressant-like effects of the novel kappa opioid antagonist MCL-144B in the forced swim test. Pharmacology, 81:229-235, 2008.
  7. Carey A.N., Borozny K., Aldrich J.A. and McLaughlin J.P.: Prevention of reinstatement of cocaine-conditioned place preference by the novel peptide kappa opioid receptor antagonist, Arodyn. European Journal of Pharmacology, 569: 84-89, 2007.
  8. McLaughlin, J.P., Li, S., Valdez, J., Chavkin, T.A. and Chavkin, C.: Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology, 31: 1241-1248, 2006.
  9. McLaughlin, J.P., Land, B.B., Li, S., Pintar, J.E. and Chavkin, C.: Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology, 31: 787-794, 2006.
  10. Xu, M., Petraschka, M., McLaughlin, J.P., Westenbroek, R.E., Caron, M.G., Lefkowitz, R.J., Czyzyk T.A., Pintar J.E., Terman G.W. and Chavkin, C.: Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. J. Neurosci., 24: 4576-4584, 2004.
  11. McLaughlin, J.P., Myers, L.C., Zarek, P.E., Caron M.G., Lefkowitz R.J., Czyzyk T.A., Pintar J.E. and Chavkin, C.: Prolonged kappa-opioid receptor phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic tolerance. J. Biol. Chem., 279: 1810-1818, 2004.
  12. McLaughlin, J.P., Xu M., Mackie, K. and Chavkin, C.: Phosphorylation of a carboxy-terminal serine within the kappa opioid receptor produces desensitization and internalization. J. Biol. Chem., 278: 34631-34640, 2003.
  13. McLaughlin, J.P., Marton-Popovici M. and Chavkin, C.: Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J. Neurosci. 23: 5674-5683, 2003.
  14. Bidlack, J.M., Cohen D.J., McLaughlin, J.P., Lou, R., Ye, Y. and Wentland, M.P.: 8-Carboxamidocyclazocine: A long-acting, novel benzomorphan. J. Pharmacol. Exp. Ther., 302: 374-380, 2002.
  15. Chavkin, C., McLaughlin, J.P. and Celver, J.P.: Regulation of opioid receptor function by chronic agonist exposure: constitutive activity and desensitization. Mol. Pharmacol., 60: 20-25, 2001.
  16. McLaughlin, J.P. and Chavkin, C.: Tyrosine phosphorylation of the mu opioid receptor regulates agonist intrinsic efficacy. Mol. Pharmacol., 59: 1360-1368, 2001.
  17. Appleyard, S.M., McLaughlin, J.P. and Chavkin, C.: Tyrosine phosphorylation of the kappa opioid receptor regulates agonist efficacy. J. Biol. Chem., 275: 38281-38285, 2000.
  18. Bidlack, J.M., McLaughlin, J.P. and Wentland, M.P.: Partial opioids. Medications for the treatment of pain and drug abuse. Ann NY Acad. Sci., 909: 1-11, 2000.
  19. Xie, W., Samoriski, G.M., McLaughlin, J.P., Rosomer, V., Smrcka, A., Hinkle, P.M., Bidlack, J.M., Gross, R.A., Jiang, H. and Wu, D.: Genetic alteration of PLCß3 expression modulates behavioral and cellular responses to opioids. Proc. Natl. Acad. Sci. USA., 96: 10385-10390, 1999.
  20. McLaughlin, J.P., Hill, K.P., Jiang, Q., Sebastian, A., Archer, S. and Bidlack, J.M.: Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: In vivo and in vitro characterization of μ-selective opioid agonist and antagonist activity. J. Pharmacol. Exp. Ther., 289: 304-311, 1999.
  21. McLaughlin, J.P., Sebastian, A., Archer, S. and Bidlack, J.M.: 14ß-Chlorocinnamoylamino derivatives of metopon: mu-selective irreversible antagonists. Eur. J. Pharmacol., 320: 121-129, 1997.
  22. McLaughlin, J.P., Nowak, D., Sebastian, A., Schultz, A.G. and Bidlack, J.M.: Metopon and two unique derivatives: opioid affinity and selectivity. Eur. J. Pharmacol., 294: 201-206, 1995.
  23. McLaughlin, J.P., Sebastian, A., Archer, S. and Bidlack, J.M.: 14ß-Chlorocinnamoylamino derivatives of metopon interact differentially with the mu opioid receptor. Regulatory Peptides, 54: 187-188, 1994.
Copyright © 2010 Torrey Pines Institute for Molecular Studies. All rights reserved.